SGLT2 inhibitors and the changing landscape for treatment of diabetes
Shuangbo Liu,1 Anna Lam,2 Arslan Wazir,1 Asim N Cheema11Terrence Donnelly Heart Centre, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; 2Division of Endocrinology, University of Alberta, Edmonton, Alberta, CanadaAbstract: Type 2 diabetes mellitus has become an epide...
Guardado en:
Autores principales: | Liu S, Lam A, Wazir A, Cheema AN |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6d6b83cb2f074f5bbf94386e9a47467a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review
por: Aurélie Pahud de Mortanges, et al.
Publicado: (2021) -
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
por: Simes BC, et al.
Publicado: (2019) -
Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
por: Yaohui Jiang, et al.
Publicado: (2021) -
Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
por: Liu Y, et al.
Publicado: (2021) -
12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
por: Perna S, et al.
Publicado: (2018)